Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.

BACKGROUND: Two parallel studies evaluated safety and immunogenicity of a prophylactic HIV-1 vaccine in 192 HIV-seronegative, low-risk volunteers. Modified vaccinia virus Ankara (MVA) and plasmid DNA (pTHr) expressed HIV-1 clade A gag p24 and p17 fused to a string of 25 overlapping CD8+ T cell epito...

Full description

Bibliographic Details
Main Authors: Peters, B, Jaoko, W, Vardas, E, Panayotakopoulos, G, Fast, P, Schmidt, C, Gilmour, J, Bogoshi, M, Omosa-Manyonyi, G, Dally, L, Klavinskis, L, Farah, B, Tarragona, T, Bart, P, Robinson, A, Pieterse, C, Stevens, W, Thomas, R, Barin, B, Mcmichael, A, McIntyre, J, Pantaleo, G, Hanke, T, Bwayo, J
Format: Conference item
Published: 2007

Similar Items